Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia

from Oncology Learning Network · host HMP Global

Elias Jabbour, MD, MD Anderson Cancer Center, Houston, Texas, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Episode metadata supplied by the publisher feed · Published Jun 5, 2026

Embed this episode

Attribution link and audio player

Ready to play

Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia

0:00 3:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 3 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on June 5, 2026.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!